Key Takeaways:
Medpace Holdings Inc. reported first-quarter revenue of $706.6 million, a 26.5% increase from the prior-year period, showing strong growth amid an ongoing investor lawsuit.
"Individual officers who sign SEC certifications bear personal responsibility for the accuracy of corporate disclosures," Joseph E. Levi of Levi & Korsinsky, LLP, said in a statement regarding the lawsuit.
The clinical research organization's revenue grew from $558.6 million in the first quarter of 2025. On a constant currency basis, revenue increased 25.8%. The company did not disclose earnings per share or guidance in the initial announcement.
The strong revenue report contrasts with recent controversy. A securities class action lawsuit alleges executives, including President Jesse J. Geiger, made misleading statements about the company's book-to-bill ratio, which led to a 15.9% stock drop on February 10, 2026.
The securities class action covers investors who purchased Medpace stock between April 22, 2025, and February 9, 2026. The complaint, filed by Levi & Korsinsky, LLP, names the company, CEO August James Troendle, President Jesse J. Geiger, and CFO Kevin M. Brady as defendants.
The action contends that executives knew or recklessly disregarded that backlog cancellations were accelerating and that the company's projected 1.15x book-to-bill ratio for the second half of fiscal 2025 was not achievable. Medpace shares fell $84.30 per share after the company revealed a Q4 2025 book-to-bill ratio of just 1.04x.
The lawsuit asserts that Geiger, as a controlling person, had the authority to control the contents of Medpace's public disclosures and had access to non-public information about the adverse trends.
The strong revenue growth may signal to investors that operational performance remains solid despite the legal challenges. Investors will look for the company’s formal response to the allegations and any updates on the class action lawsuit, which has a lead plaintiff deadline of June 8, 2026.
This article is for informational purposes only and does not constitute investment advice.
